Your session is about to expire
← Back to Search
Anti-thrombotic
Thrombolytic Therapy for Ischemic Stroke
Phase 1 & 2
Recruiting
Research Sponsored by Baylor College of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Anterior Circulation stroke within the last six hours
Posterior Circulation stroke within the last 12 hours
Timeline
Screening 3 weeks
Treatment Varies
Follow Up ninety days
Awards & highlights
Study Summary
This trial is testing the use of a GP IIb/IIIa inhibitor (abciximab) in patients with stroke.
Who is the study for?
This trial is for adults who've had a stroke affecting the brain's anterior region within 6 hours or posterior region within 12 hours. They must not have signs of non-ischemic causes like hemorrhage or tumor, severe kidney/liver issues, very low platelet counts, or be at high risk of bleeding.Check my eligibility
What is being tested?
The study tests how well GP IIb/IIIa inhibitors work in patients with ischemic strokes. These are potent platelet inhibitors already used for heart conditions and might help when given alongside standard treatments like t-PA or thrombectomy.See study design
What are the potential side effects?
Potential side effects may include increased risk of bleeding due to the drug's ability to prevent blood clots. This could lead to complications such as bruising easily, nosebleeds, and in rare cases more serious internal bleeding.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I had a stroke affecting the front part of my brain within the last 6 hours.
Select...
I had a stroke in the back part of my brain within the last 12 hours.
Select...
I am 18 years old or older.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ ninety days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~ninety days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Ninety day functional outcomes
Trial Design
1Treatment groups
Experimental Treatment
Group I: Measurement of Platelet functionExperimental Treatment1 Intervention
Patients with ischemic stroke may be given alteplase or other thrombolytic. Additionally, patients may be given IV platelet inhibitors and subjected to thrombectomy. Platelet functions are measured after intervention.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Thrombolytic Agent
2021
N/A
~490
Find a Location
Who is running the clinical trial?
Baylor College of MedicineLead Sponsor
1,001 Previous Clinical Trials
6,002,222 Total Patients Enrolled
4 Trials studying Stroke
1,198 Patients Enrolled for Stroke
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I had a stroke affecting the front part of my brain within the last 6 hours.I had a stroke in the back part of my brain within the last 12 hours.My INR is above 2.5 while I'm on warfarin.I am 18 years old or older.My doctors think I have a high risk of bleeding in my brain or body.Your blood clotting time is too long.I show signs of liver failure or have high liver enzyme levels.Your creatinine levels are higher than 2.Your first head CT scan shows that your stroke-like symptoms are not caused by a blood clot but by bleeding or a tumor.Your blood platelet count is less than 100,000.My PTT levels are above 75 while I'm on heparin.I was dependent on others for daily activities before my current illness.
Research Study Groups:
This trial has the following groups:- Group 1: Measurement of Platelet function
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
How many subjects are participating in this experiment?
"Affirmative. Per information on clinicaltrials.gov, this research study is presently accepting participants. Originally posted in February 18th 2022 and last updated June 8th 2022, the trial needs to enlist 30 volunteers from 1 site."
Answered by AI
Are there any remaining vacancies for this medical trial?
"According to clinicaltrials.gov, this research is currently seeking participants - the initial posting being on February 18th 2022 and the most recent update occurring June 8th 2022."
Answered by AI
Who else is applying?
What state do they live in?
Texas
What site did they apply to?
Michael E. DeBakey VA Medical Center
What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
0
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger